Clinical Trials Logo

Bile Duct Cancer clinical trials

View clinical trials related to Bile Duct Cancer.

Filter by:

NCT ID: NCT00628186 Completed - Pancreatic Cancer Clinical Trials

Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy

Start date: April 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to determine which stent type is effective in the decrease of postoperative stay and complications across pancreaticojejunostomy after pancreaticoduodenectomy.

NCT ID: NCT00579865 Completed - Liver Cancer Clinical Trials

Quality Of Life in Patients With Malignant Biliary Obstruction

Start date: May 2005
Phase: N/A
Study type: Observational

You may have symptoms like itching, abdominal pain, loss of appetite, fatigue, fevers and chills. The treatment you will receive to relieve the blockage is also intended to relieve symptoms and improve your quality of life. The purpose of this study is to find out if relieving the blockage in your bile duct improves your quality of life.

NCT ID: NCT00280709 Completed - Pancreatic Cancer Clinical Trials

Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction

Start date: January 2006
Phase: Phase 4
Study type: Interventional

The primary purpose is to compare patency of two different types of biliary metal stents, i.e. covered versus uncovered Nitinella metal stent. Secondary purposes are to determine frequency of complications in the two groups, e.g. cholecystitis, pancreatitis, and cholangitis.

NCT ID: NCT00183846 Completed - Pancreatic Cancer Clinical Trials

Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers

Start date: December 2000
Phase: Phase 1
Study type: Interventional

This study is for people with advanced cancer of the digestive tract and cancer that cannot be completely removed by surgery. Radiation therapy is commonly used in the treatment of these types of cancer in combination with a chemotherapy drug, called 5-fluorouracil (5-FU). In this study, doctors will administer the standard dose of radiation therapy in combination with an investigational chemotherapy drug, called irinotecan. Irinotecan can decrease the size of tumors and also appears to increase the effectiveness of radiation. The purpose of this study is to determine the highest dose of irinotecan that can be given safely in combination with radiation therapy, and to determine the side effects when these two treatments are given together. Irinotecan is approved by the Food and Drug Administration (FDA) for the treatment of colon cancer, but is not approved for cancers of the digestive tract. However, the FDA is allowing its use in this research study.